Clinical and economic outcomes by first-line treatment among women with HR+/HER2– metastatic breast cancer in a large US health plan database-Reference-Cited by-同舟云学术

Clinical and economic outcomes by first-line treatment among women with HR+/HER2– metastatic breast cancer in a large US health plan database

Published:2016-05-12 Issue:8 Volume:32 Page:1417-1423
ISSN:0300-7995
Container-title:Current Medical Research and Opinion
language:en
Short-container-title:Current Medical Research and Opinion

Author:

Burton Tanya¹,Byfield Stacey DaCosta²,Smith Gregory L.³,Zanotti Giovanni³,Bell Timothy J.³,Perkins Julia J.³,Horblyuk Ruslan³,Teitelbaum April⁴

Affiliation:

1. Optum, Waltham, MA, USA;

2. Optum, Eden Prairie, MN, USA;

3. Pfizer Inc, New York, NY, USA;

4. HemeOnc Associates, Carlsbad, CA, USA

Publisher

Informa UK Limited

Subject

General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/03007995.2016.1178108

Reference13 articles.

1. American Cancer Society. Breast Cancer: facts & figures 2013–2014. Atlanta, GA: American Cancer Society, 2013 Available at: http://www.cancer.org/acs/groups/content/@research/documents/document/acspc-042725.pdf. Accessed October 28, 2015

2. Metastatic breast cancer: prolongation of survival in routine care is restricted to hormone-receptor- and Her2-positive tumors

3. National Comprehensive Cancer Network. Clinical practice guidelines in oncology (NCCN Guidelines). Breast Cancer. Version 1.2016. Fort Washington, PA: National Comprehensive Cancer Network, 2015. Available at: https://www.nccn.org/store/login/login.aspx?ReturnURL=http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed December 18, 2015

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world Data on First-line Systemic Therapy for Hormone Receptor-positive HER2-negative Metastatic Breast Cancer: A Trend Shift in the Era of CDK 4/6 Inhibitors;Clinical Breast Cancer;2021-12

2. An evaluation of the healthcare costs of metastatic breast cancer;Medicine;2021-10-29

3. Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population;Breast Cancer Research and Treatment;2021-08-19

4. Defining treatment regimens and lines of therapy using real-world data in oncology;Future Oncology;2021-05

5. Assessing direct costs of treating metastatic triple-negative breast cancer in the USA;Journal of Comparative Effectiveness Research;2021-02